Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
September 17, 201211m 12s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.